Poxvirus protein N1L targets the IKK Kinase complex, inhibits signaling to NF-κB by the Tumor Necrosis Factor superfamily of receptors, and inhibits NF-κB and IRF3 signaling by Toll-like receptors.

Gary DiPerna*, Julianne Stack#, Andrew G. Bowie#, Annemarie Boyd*, Girish Kotwal^**, Zhouning Zhang^, Sheila Arvikar*, Eicke Latz*, Katherine A Fitzgerald*, and William L. Marshall*^

#Viral Immune Evasion Group, Department of Biochemistry, Trinity College, Dublin 2 Ireland, ^Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville, KY 40202 USA, Division of Medical Virology, University of Cape Town Medical School, **Institute of Infectious Diseases and Molecular Medicine, Observatory, Cape Town 7925, South Africa, *Department of Medicine, University of Massachusetts Medical School, 364 Plantation St., Worcester, MA 01605, USA.

^Corresponding author: FAX:(508)-856-2020, Phone:(508)-856-7513, e-mail:william.marshall@umassmed.edu

Running Title: Poxvirus N1L targets IKK complex to inhibit NF-κB and IRF3 signaling
Summary

Poxviruses encode proteins that suppress host immune responses, including secreted decoy receptors for proinflammatory cytokines such as interleukin-1 (IL-1) and the vaccinia virus proteins A46R and A52R that inhibit intracellular signaling by members of the IL-1 receptor (IL-1R) and Toll-like receptor (TLR) family. In vivo, the TLRs mediate the innate immune response by serving as pathogen recognition receptors, whose oligomerized intracellular Toll/IL-1 receptor (TIR) domains can initiate innate immune signaling. A family of TIR domain-containing adapter molecules transduces signals from engaged receptors that ultimately activate NF-$\kappa$B and/or IRF3 to induce pro-inflammatory cytokines. Database searches detected a significant similarity between the N1L protein of vaccinia virus and A52R, a poxvirus inhibitor of TIR signaling. Compared to other poxvirus virulence factors, the poxvirus N1L protein strongly affects virulence in vivo, however the precise target of N1L was previously unknown. Here we show that N1L suppresses NF-$\kappa$B activation following engagement of Toll/IL-1 receptors, tumor necrosis factor receptors and lymphotoxin receptors. N1L inhibited receptor-, adapter-, TRAF-, and IKK-$\alpha$ and IKK-$\beta$-dependent signaling to NF-$\kappa$B. N1L associated with several components of the multi-subunit I-$\kappa$B kinase complex, most strongly associating with the kinase, TBK1. Together these findings are consistent with the hypothesis that N1L disrupts signaling to NF-$\kappa$B by Toll/IL-1Rs and TNF superfamily receptors by targeting the IKK complex for inhibition. Furthermore, N1L inhibited interferon regulatory factor 3 (IRF3) signaling, which is also regulated by TBK1. These studies define a role for N1L as an immunomodulator of innate immunity by targeting components of NF-$\kappa$B and IRF3 signaling pathways.
Introduction

Vaccinia virus is a poxvirus that was used over 20 years ago to eradicate variola virus infection (smallpox) (1). The variola and vaccinia orthopoxviruses express homologs of proteins encoded by the immune response genes of their hosts (1). These homologs include secreted decoy receptors for interleukins 1 and 18 (IL-1 and IL-18) (1). Vaccinia also encodes proteins that inhibit intracellular signaling by the toll-like receptor family (TLRs) (2). In vivo, the TLRs mediate the innate immune response by serving as pathogen-associated pattern recognition receptors (3), whose oligomerized intracellular regions can cluster intracellular Toll/IL-1 receptor (TIR) domains. Clustering of homotypically-associated TIR domain-containing adapters transduces signals that ultimately activate NF-κB and cytokine response pathways (4). Vaccinia virus encodes the A46R and A52R proteins, which have been shown to act as dominant negative inhibitors of TIR signaling. A46R has been shown to inhibit IL-1 signaling, while A52R interferes with IL-1, IL-18 and TLR signaling, thereby inhibiting both the innate and ultimately the adaptive immune response (2).

Signals initiated by several pro-inflammatory cytokines, or by Toll receptor engagement, lead to TIR clustering that recruits one or more TIR adapter proteins: Mal/TIRAP, TRIF/TICAM-1, MyD88 and TRAM/TIRP/TICAM-2 (5-12). Recruitment of these TIR-domain-containing adapter proteins leads to the recruitment of IRAK family members, which subsequently activate TRAF6 (13). Activated TRAF6 is thought to auto-ubiquitinate, and then bind and activate a TAK1-containing complex. TAK1 then likely phosphorylates and activates the IκB kinase (IKK) complex (14). The IKK
complex is composed of two structurally similar kinases, IKK-α and IKK-β, as well as the non-catalytic regulatory subunit IKK-γ (also called NEMO). The activated IKK complex phosphorylates IκBα on serine 32 and 36 leading to its polyubiquitination and degradation by the proteasome. Degradation of IκB permits nuclear translocation of NFκB, ultimately driving transcription of NFκB responsive genes (reviewed in (15,16)). Current data indicates that the IKK complex is critical for IκB degradation and NF-κB activation in response to pro-inflammatory signals.

Vaccinia virus was known to encode two proteins that inhibit the components of the Toll and IL-1 signaling pathways (2). Other poxviruses encode several uncharacterized homologs of these Toll/IL-1R signaling inhibitors (17). We conducted database searches that detected a significant similarity among previously identified poxvirus inhibitors of Toll/IL-1R signaling (2) and the N1L protein of vaccinia virus. N1L is among the strongest determinants of vaccinia virus virulence (18,19). Whereas N1L has modest effects on adaptive immunity, N1L suppresses initial host defenses against vaccinia virus challenge by a factor of 10⁴ (18), suggesting that N1L inhibits innate immunity. However, the mechanism whereby the N1L virulence factor functions was previously unknown (18,19).

Here it is shown that signaling via TNF-α, lymphotoxins and Toll/IL-1R family members are fundamental immune response pathways inhibited by N1L. Signaling by inflammatory cytokines, TIR adapter molecules, and several downstream components of the NFκB signaling pathway are inhibited by N1L. N1L co-immunoprecipitates along with members of the IKK complex. N1L also inhibited the activation of interferon regulatory factor 3 (IRF3) in response to double stranded RNA stimulation of TLR3 or
transfection of a TIR adapter that mediates signaling to IRF3. Taken together, these findings are consistent with the hypothesis that N1L disrupts the IRF3/NFκB signaling pathways by targeting the IKK kinase complex, thereby establishing the role of N1L as a viral immunomodulator of innate immunity.

**Methods**

**Cell culture and cell lines.** Cells were maintained at 37 °C in a humidified atmosphere of 5% CO2. HEK 293 cell stable transfectants were maintained in DMEM in the presence of 400 μg/ml geneticin sulfate, 10% heat-inactivated bovine calf serum, 600 μg/ml L-glutamine, penicillin-streptomycin (Gibco BRL), and 20 μg/ml ciprofloxacin. Wild type HEK cells were maintained in the identical medium without geneticin. The HEK cells stably expressing CD14, MD2 and either TLR2, TLR3, or TLR4 have been described previously (6,20,21). For use in transfection assays, HEK 293 were typically seeded at 2x10⁴ cells per ml in 96-well plates 24 h prior to transfection.

**Vector construction and plasmids.** An N1L construct was created by PCR amplification of the N1L open reading frame of vaccinia virus (Copenhagen strain) DNA donated by Francis Ennis and Masanori Terajima (University of Massachusetts Medical School, Worcester, MA). To create N1L encoding vectors, N1L was amplified using the primers: 5’-ATGAGGACTCTACTTATTAGA-3’ and 5’-TTATTTTTCACCATATAGTC-3’. The PCR product was TA cloned into pCR3.1 (Invitrogen, Carlsbad, CA). The resulting construct, pCR3.1N1L, was sequenced in both directions using bGH reverse and T7 forward primers. N1L cDNA was subcloned into the pDNR-dual vector, which encodes a C-terminal 6Xhistidine-arginine (HN) tag (BDBiosciences). pDNRN1L-6XHN underwent
recombination with a hemagglutinin (HA)-acceptor vector yielding a HA-N1L-HN tagged version of N1L. The resulting construct was also sequenced. pcDNA3.1N1L was constructed by ligating BamHI-NotI digested pCR3.1N1L into pcDNA3.1(+) that had been identically digested. FLAG-tagged Mal, TRIF, IKK\(_\alpha\) TBK1 and the pGL3-5X\(_{\text{K}}\)B-luc plasmid were previously described (6). The ISG54 ISRE luciferase vector was purchased from Stratagene. (FLAG-tagged TRAM was also previously described (6). N-terminally FLAG-tagged IKK-\(\alpha\) (22), and a C-terminally FLAG-tagged modification of IKK-\(\beta\) (23), FLAG-TRAF6, and FLAG-TRAF2 (24) were gifts of D. Goeddel (Tularik, Inc., San Francisco, CA). The plasmid encoding BZLF1 was a gift of Joan Mannick (University of Mass. Medical School, Worcester, MA). The plasmid thymidine kinase Renilla luciferase (pTk-Renilla) was purchased from Promega Inc. (Madison, WI). The plasmid encoding MyD88 was from M. Muzio (Mario Negri Institute, Milan, Italy). Chimeric TLR receptors CD4-TLR1, CD4-TLR2, CD4-TLR4, and CD4-TLR6 composed of the extracellular domain of CD4 fused to the transmembrane domain and cytosolic tail of the TLR were gifts from R. Medzhitov (Yale University, New Haven, CT).

**Reagents.** Poly I:C was purchased from Amersham Biosciences. The Mycoplasma fermentans-derived membrane macrophage-activating lipopeptide of 2 kDa (MALP-2) was generated as previously described (25), and was obtained both from P. F. Mühlradt (Gesellschaft für Biotechnologische Forschung, Braunschweig, Germany) and from G. Rawadi (Institute Pasteur, Paris, France). Bacterial lipopolysaccharide (LPS) derived from *E. coli* strain 011:B4 was purchased from Sigma-Aldrich, and either used directly or purified as described (26). Human IL-1-\(\beta\) and TNF-\(\alpha\) were purchased from Cell Sciences (Woburn, MA).
Transient transfection and NFκB or IRF3 reporter assays: HEK cells were transfected with vectors encoding components of either the TIR or the lymphotoxin signal transduction pathways. HEK cells were co-transfected with ISRE luciferase vector or NFκB luciferase vector, Tk-Renilla luciferase vector, N1L or empty vector, and in certain cases with a component of the NFκB signaling pathway. All HEK 293 cell transfections were performed using GeneJuice (Novagen, Madison, WI) according to the manufacturer's recommendations. Transfection efficiency was normalized by transfection of cells with a plasmid encoding Renilla luciferase. The amount of DNA transfected was equalized among experiments by the addition of various amounts of the appropriate empty vector plasmid. To assay firefly and Renilla luciferase activity, cells were lysed using passive lysis buffer (Promega, Madison, WI), and luciferase activity was determined by standard protocols, using methods as described (7). Results are presented as mean +/- S.E. and are consistent with the results of at least three separate experiments. Statistical analyses were via an unpaired, two tailed t test performed using Graph Pad Prism software.

Co-immunoprecipitation. HEK cells were cotransfected with HA/HN-tagged N1L and a FLAG-tagged component of the NFκB signal transduction system, as indicated in the Figure legend. For each transfection, a confluent T25 flask of HEK 293 cells was trypsinized and washed. Cells were then lysed on ice for an hour in 100 ul of a lysis buffer comprised of 0.5% NP-40, 300 mM NaCl, 50 mM Tris pH 7.6, and Complete™ protease inhibitor cocktails (Roche Diagnostic). Lysates were centrifuged at 4°C for 20 minutes at 14,000 X g, and lysates were immunoprecipitated with anti-HN antibody (BDBiosciences) bound to Protein A Sepharose beads (Amersham Biosciences).
Immunoprecipitated proteins were boiled in Laemmli buffer for 5 minutes and electrophoresed on a 15% SDS-PAGE gel. Transfer to 0.45 um PVDF membrane was followed by blocking, and then the blot was probed with anti-FLAG monoclonal antibodies (M2, Sigma-Aldrich) and later probed with a donkey anti-mouse horseradish peroxidase (Amersham, Arlington Heights, IL) for 30 minutes essentially as described (27). In certain experiments the primary antibody step was followed by incubation with a horseradish peroxidase conjugated antibody that recognizes native rabbit IgG (TrueBlot™, eBioscience, San Diego, CA). Between the blocking and antibody incubation steps the PVDF membrane was washed repeatedly with PBS/Tween 20. Resulting bands on the immunoblot were developed with the ECL developer system (Amersham Biosciences) and visualized on a Fuji Imager. Immunoprecipitation with anti-HN-coated Protein A Sepharose beads followed by immunoblot with anti-FLAG antibody was used to confirm the specificity of the results.

In other experiments, anti-HN antibodies (Clontech) were used to co-immunoprecipitate HA-TANK and HA-IKK\(\alpha\) alongside HA-N1L-HN. Subsequently, an immunoblot with anti-HA antibody (Clontech) was performed as above. Finally, anti-IKK\(\alpha\) antibody (Cell Sciences) was used to immunoblot lysates from the indicated transfectants that were immunoprecipitated with anti-FLAG antibody. Presence of IKK\(\alpha\) in lysates was also confirmed.

In vitro transcription and translation and protein-protein interaction: In vitro transcription and translation were performed essentially according to the manufacturer’s instructions as outlined in the TNT Quick kit from Promega (Madison, WI) using 0.5 ug of the indicated DNA template, a biotinylated lysine label (Pathdetect, Promega). After
confirmation of protein expression with an aliquot of protein, aliquots of N1L and various IKK components were incubated in TWB buffer (20 mM HEPES, pH 7.9, 60 mM NaCl, 1 mM DTT, 6 mM MgCl2, 8.2% glycerol, and 0.1 mM EDTA) and Complete™ protease inhibitor (Roche) at 4C for 1 hour. FLAG-tagged proteins were immunoprecipitated with Protein G Sepharose coupled anti-FLAG antibody, or HA-tagged proteins were immunoprecipitated with Protein A Sepharose coupled anti-HA antibody and then washed 4 times in hypotonic lysis buffer (see above). Samples were then analyzed by SDS-PAGE and blotted onto PVDF membranes, which were blocked in PBS, 0.05% Tween 20 and subsequently incubated with streptavidin HRP. Labeled proteins on the blot were detected by chemiluminescence (Promega), and images were captured on a Fuji Imager.

Results

The N1L proteins from vaccinia and other poxviruses have sequence similarity to inhibitors of NF-κB signaling. The amino acid sequence of N1L is relatively conserved from sheepox virus to vaccinia, and N1L amino acid sequence is almost identical among most vaccinia viruses (19). Vaccinia virus encodes two known inhibitors of IL-1 and TLR signaling that are similar in sequence (2), albeit functionally distinct inhibitors of NF-κB signaling (27). Several poxvirus proteins have been noted as potential inhibitors of NF-κB signaling based upon their sequence similarity (17,28) to known poxvirus inhibitors of NF-κB stimulation (2,27). Our database searches demonstrate that N1L is very similar (PHI-BLAST e=3x10^{-12}) to A52R, which has been
shown to inhibit Toll, IL-1β, and IL-18 signaling to NF-κB (2). Because of this sequence similarity, we hypothesized that N1L inhibited signaling to NF-κB.

**N1L inhibits signaling to NF-κB by IL-1β, TNF-α and lymphotoxins.** Because N1L has sequence similarity to poxvirus inhibitors of signaling by IL-1 and TLRs (2), we first tested the hypothesis that N1L inhibits IL-1 function. Stimulation of NF-κB activity by IL-1β was significantly suppressed by N1L (Figure 1A, p=0.0084). N1L also inhibited stimulation of NF-κB by TNF-α signaling (Figure 1A, p=0.015). Next, the effect of N1L on stimulation by the lymphotoxin family member, LIGHT (29), was examined. In a simultaneous experiment (Figure 1A), N1L inhibited LIGHT-mediated NF-κB signaling five fold compared to vector transfected cells, which was significant (p=0.02). The finding that N1L also inhibited signaling by TNF-α and LIGHT (Figure 1A), whereas A52R does not block TNF-α (2), indicated that N1L was a functionally distinct vaccinia virus inhibitor of signaling to NF-κB.

In order to determine the specificity of the inhibition of NF-κB activity by N1L, the activity of N1L on reporter constructs other than NF-κB was tested. N1L was transfected with one of three reporter constructs: NF-κB luciferase, AP-1 luciferase, or NFAT luciferase. Reporter constructs were co-transfected with the Epstein Barr virus transactivator BZLF1, which both binds to and stimulates transcription from AP-1 sites (30) while inhibiting NF-κB activity in lymphocytes (31). Despite two-fold inhibition of basal NF-κB activity, N1L does not inhibit AP-1 luciferase activity (Figure 1B). BZLF1 suppresses NF-κB activity, consistent with results in lymphocytes (31). NFAT luciferase activity is not observed. Thus, the inhibitory effect of N1L is specific to the NF-κB and not the AP-1 pathway. In separate experiments, no cytotoxicity was evident in N1L.
transfected cells based upon Annexin V staining or flow cytometric analysis (data not shown). Overall, these data indicate that N1L specifically downmodulates signaling by NFκB that occurs in response to several inflammatory cytokines.

N1L inhibits signaling to NFκB by Toll receptors TLR 2, TLR 3 and TLR4. The hypothesis that N1L inhibits Toll receptor signaling was considered for several reasons. First, N1L is possesses sequence similarity to vaccinia virus inhibitors of toll-like receptor (TLR) signaling (2). Second, N1L inhibits IL-1β signaling (Figure 1A), suggesting that N1L may interact with a component of the Toll/IL-1 signaling pathway. Finally, whereas N1L does not appreciably inhibit adaptive immunity, such as antibody response and cytotoxic T lymphocyte activity, N1L significantly increases the ability of vaccinia virus to overcome host defenses to initial viral challenge (18), suggesting that N1L inhibits innate immunity. Therefore, we hypothesized that N1L is involved in inhibition of the Toll receptors that mediate an antiviral innate immune response.

To test whether N1L inhibited NF-κB activation by TLR2, TLR3 or TLR4, we used two different approaches: a ligand-dependent system utilizing stable transfection of HEK293 cells and a transient, constitutively-active TLR expression system. HEK 293 cells stably expressing either TLR2, TLR3 or TLR4 were treated with their respective ligands: lipopeptide, the dsRNA mimetic, poly I:C, or bacterial lipopolysaccharide (LPS) (8,32,33), and analyzed as in Figure 1. Chimeric versions of the TLRs, comprising the murine CD4 extracellular domain fused to the cytoplasmic domain of a given human TLR have proved useful in probing TLR signalling pathways (34). Some TLR cytoplasmic domains can induce gene expression as homodimers (TLR4 and TLR5), while others signal as heterodimers (TLR1, TLR2 and TLR6) (35). The extracellular
domain of CD4 renders the TLR chimera constructs constitutively active. Using these chimeras, TLR signalling can be examined in the absence of an exogenous activator.

Signaling by TLR2 was first analyzed in stable HEK 293 transfectants. N1L inhibits TLR2-dependent signaling in response to lipopeptide agonists (Figure 2A top panel, p=0.0014 for unpurified LPS, p=0.044 for MALP-2). Use of transient cotransfection of N1L and constitutively active chimeric CD4-TLR1, CD4-TLR2, CD4-TLR4, and CD4-TLR 6 demonstrates N1L-mediated inhibition of TLR2 signaling in conjunction with TLR1 (Figure 2A middle panel) (p=0.0246) or TLR6 (Figure 2A bottom panel) (p=0.0017).

TLR3, which is known to interact with viral dsRNA, was analyzed next. The TLR3 ligand poly I:C was used to stimulate stable TLR3 transfectants. Twelve-fold inhibition by N1L of HEK293 cells stably expressing TLR3 is observed (Figure 2B, top panel, p=0.0004). N1L inhibits signaling induced by poly I:C treatment of HEK cells transiently transfected with TLR3 (p=0.0174) (Figure 2B, bottom panel). TLR4 function was next examined and is inhibited by N1L (Fig. 2C, top panel, p=0.011). CD4-TLR4 signaling is inhibited by N1L (p=0.0146) (Figure 2C, bottom panel). Given that N1L inhibits signaling by all Toll receptors tested, one logical candidate for inhibition by N1L was the TIR adapters that transduce signals from Toll, IL-1 and IL-18 receptors (4,36).

**Signaling to NF-κB by TIR adapter molecules is inhibited by N1L.** To identify the mechanism whereby Toll, IL-1, TNF-α and lymphotoxin signal transduction pathways are inhibited by N1L (Figure 1), we studied the effect of N1L upon membrane-proximal components of the Toll/IL-1R signaling pathways such as Mal/TIRAP, TRIF/TICAM-1, MyD88 (7-11) and TRAM (5,6) (Figure 3A). Signaling via TRIF/TICAM-1 is especially
relevant to innate immunity against vaccinia virus since mutations in TRIF are associated with a 20-fold rise in vaccinia virus production in infected macrophages (37). N1L inhibits TRAM and MyD88 activation of NF-κB fourfold, which is significant (p<0.002). N1L inhibits Mal/TIRAP and TRIF activation of NF-κB by six fold (Figure 3A, p<0.005). In general, the N1L-induced inhibition of the TIR adapters is comparable, suggesting that a common signaling component downstream in the Toll/IL-1R signaling pathway might be inhibited. This suggested the hypothesis that TRAF family members or components of the IKK complex might be targeted by N1L. This hypothesis that the IKK complex is the target of N1L is consistent with the fact that TIR-independent signaling, such as signaling induced by TNF and lymphotoxins, is inhibited by N1L (Figure 1A).

**NF-κB signaling by TRAF2 and TRAF6 is inhibited by N1L.** Signals initiated by pro-inflammatory cytokines or Toll receptor engagement lead to the activation of a family of serine/threonine kinases, the IRAK family, and TRAF6, ultimately activating the I-κB kinase (IKK) complex and leading to NF-κB translocation (15). Furthermore, because of the known interaction between A52R and TRAF6 (27) and because N1L has sequence similarity to vaccinia A52R, functional interactions between N1L and TRAF6 were examined next.

Figure 3B demonstrates that signaling by ectopic overexpression of TRAF2 or TRAF6 is inhibited by N1L. In Figure 3B, fourfold inhibition of TRAF6 signaling and a fivefold inhibition of TRAF2 signaling are observed, which is significant (p=0.0002 and p=0.05, respectively). Although it is formally possible that N1L individually targets both
TRAF2 and TRAF6 for inhibition, the data of Figure 3 suggests that inhibition by N1L may occur downstream of these TRAF proteins.

NF-κB signaling by TBK1, IKK-α and IKK-β is inhibited by N1L. Several lines of evidence pointed to the IKK complex as being central to the function of N1L. Signaling by IL-1β, TNF-α, Toll and LIGHT converges at the IKK complex and is inhibited by N1L (Figure 1 and 2). Furthermore, both IKK-α and IKK-β signal downstream of the distinct TRAF2 and TRAF6 signaling pathways, which are inhibited by N1L (Figure 3). Finally, viral modulation of signaling by the IKK complex occurs via the adenovirus 14.7 kDa protein (38), which was reported to be similar to N1L (18).

In order to test the hypothesis that N1L-mediated inhibition of NF-κB signaling occurs at (or distal to) the IKK complex itself, ectopic overexpression of IKK-α and IKK-β was performed in cells transfected with N1L or empty vector (Figure 4A). The function of IKK-α and IKK-β is significantly inhibited by N1L (Figure 4A, p<0.02 for IKK-α and p<0.0066 for IKK-β). Two related kinases, IKK-ε (also designated IKK-i) and TANK-binding Kinase 1 (TBK1) (alternatively designated NAK and T2K), have been found to be part of a multiprotein complex that also contains IKK-α, IKK-β, IKK-γ and the TRAF family member associated NF-κB activator, TANK (39). The ability of N1L to inhibit these kinases was tested in Figure 4B. N1L inhibits TBK1 stimulation of NF-κB (p=0.003) and IKK-ε (p=0.01). Thus, N1L inhibits the NF-κB stimulatory function of four kinases in the IκB kinase complex.

Co-immunoprecipitation of N1L and certain NF-κB signaling components of the IKK complex. Poxvirus protein A52R physically associates with IRAK2 and TRAF6, thereby inhibiting Toll and IL-1 signaling (27). Many other inhibitors of the TLR and IL-
1R pathway physically associate with the components that they inhibit (4,32). Because N1L inhibited NF-κB signaling components at/upstream of the IKK complex (Figures 2-4), we tested for a physical association between N1L and components of the IKK complex such as IKK-α and IKK-β (Figure 5A). Two related kinases, IKK-ε and TBK1, have also been shown to be part of the IKK complex (39). Therefore, we also examined the interactions of N1L with IKK-α and TBK1 (Figure 5B and 5C).

To identify which kinases of the IKK complex associated with N1L, a 6xHN-tagged N1L fusion protein was co-expressed in HEK cells with several FLAG-tagged components of the NF-κB signal transduction system. Immunoprecipitation by anti-6xHN antibody and immunoblot with anti-FLAG antibody was performed, which revealed an association between N1L and IKK-α and IKK-β (Figure 5A-top panel). The bottom panel is an anti-HN blot of the lysates used in the immunoprecipitation, and it demonstrates approximately equal loading of HA-N1LHN-tagged protein. Thus, Figure 5A indicates that N1L can co-immunoprecipitate IKK-α and IKK-β. When the same lysate was immunoprecipitated with anti-FLAG antibody only a minimal amount of N1L fusion protein was detected, suggesting only a minimal association between IKK-α and IKK-β on the reverse immunoprecipitation (data not shown).

TBK1 and IKK-ε co-immunoprecipitate with N1L (Figures 5B and 5C). Since the association between N1L and TBK1 occurs whether either N1L or TBK1 is the protein being immunoprecipitated, these interactions in the immuonprecipitations provide further evidence that that N1L and TBK1. Figure 5 suggests an association between N1L and components of the IKK complex. IKK-α and IKK-β have been shown to form a large complex with IKK-ε, TBK1, TANK, and members of the TRAF family. IKK-ε forms
an oligomeric structure with IKK-α and IKK-β (40) associating with TANK, and thereby, TBK1 and IKK-γ (39). Furthermore, several other viral proteins that modulate signaling to NF-κB specifically target IKK-γ. Therefore, we examined interactions between N1L and IKK (Figure 6A). Figure 6A indicates that HA-IKK-γ and HA-TANK co-immunoprecipitate with N1L.

Since HA-IKK-γ co-immunoprecipitates with N1L, we considered whether N1L might disrupt the association of IKK-γ with IKK-α/β by binding to sites common to their point of physical association. Peptides containing a C-terminal motif of IKK-α/β that is required for IKK-γ binding have been shown to disrupt formation of IKK-γ:IKK-α/β complexes (41). Thus, another hypothetical mechanism of action of N1L would be to disrupt the association of IKK-γ with IKK-α/β. If N1L bound IKK-α/β directly at the IKK-γ:IKK-α/β binding site, formation of IKK-γ:IKK-α/β complexes would be inhibited. This is not seen in Figure 6B, where the association between IKK-γ:IKK-γ persists in the presence of N1L. N1L also associated with TANK (Figure 6A), which suggested that TANK, as well as TBK1, might together be direct targets of N1L. Since other poxvirus inhibitors target tandem members of the NF-κB signaling pathway (27), we sought to test whether N1L directly associated with TANK, TBK1 and IKK-γ.

In Figure 7, protein-protein interactions are compared between in vitro transcribed and translated N1L and either TBK1, IKK-γ and TANK. Aliquots of N1L and various IKK complex components were incubated, subsequently immunoprecipitated, and then analyzed by SDS-PAGE. The results in Figure 7 demonstrate a band in the N1L and TBK1 lanes at approximately 15 kilodaltons, which corresponds to the anticipated size of N1L (18). This N1L band is not present in the lanes containing in vitro
translated IKK-ε and TANK. In vitro translated/transcribed IKK-ε and TANK are each present in the lanes as indicated by a band of approximately 50 kilodaltons. These data are consistent with the finding in Figure 5 that TBK1 immunoprecipitates with N1L and N1L immunoprecipitates with TBK1. Furthermore, signaling to NF-κB is inhibited by N1L (Figures 1-4), and N1L inhibits NF-κB signaling by overexpression of TBK1 (Figure 4B). Overall, the results of Figure 7 suggest that N1L directly targets TBK1 to inhibit activation of NF-κB.

**N1L inhibits signaling by the interferon response pathway.** The host innate immune system responds to pathogens via the interferon response pathway that is induced TLR3 and TLR4 signaling in response to viruses, double stranded RNA and LPS (43). The TIR adapters TRIF and TRAM have been shown to mediate signaling via the IRF3 pathway in response to dsRNA (polyI:C) or LPS stimulation of TLR3 and 4 respectively (44). The downstream kinases involved in signaling include TBK1 (42) and IKKε (6), which phosphorylate the IRF3 transcription factor. Phosphorylation permits IRF3 activation and translocation to the nucleus where IRF3 binds co-coordinately with NF-κB to promoters such as the IFN-β promoter driving the production of cytokines such as IFN-β (6).

The observation that N1L physically targets TBK1 and IKKε (Figure 5) suggested the hypothesis that N1L would inhibit TIR adapter stimulation driving the ISRE promoter. Because N1L inhibits signaling to NF-κB, we hypothesized N1L would inhibit the activity of promoters containing both NF-κB and ISRE elements, such as the interferon beta (IFN-β) promoter. In order to test this hypothesis, N1L was cotransfected with plasmids encoding ISRE and IFN-β promoter elements driving a luciferase construct.
The top panel in Figure 8 demonstrates N1L-mediated inhibition of ISRE ($p=0.0002$) and IFN-$\beta$ ($p=0.0046$) luciferase activity. The bottom panel in Figure 8 demonstrates that N1L inhibits IRF3 signaling induced by the dsRNA ligand, poly(I:C) in TLR3 expressing HEK cells ($p=0.01$). Taken together these data indicate that N1L associates with the IKK complex and that N1L inhibits NF-$\kappa$B and IRF3 signaling.

**Discussion**

The virulence factor N1L down-modulates host cytokine responses and dysregulates innate immune signaling by IL-1R, TLRs, and members of the TNFR superfamily. The data presented here demonstrate that N1L functions, at least part, by associating with, and inhibiting, the IKK complex. The demonstration of N1L associated with several IKK complex kinases provides a mechanistic explanation for the N1L-mediated inhibition of NF-$\kappa$B activating stimuli such as cytokines (LIGHT, TNF-$\alpha$, and IL-1 in Figure 2) or overexpression of intracellular signaling components such as TRAF2, TRAF6, and the TIR-adaptors (Figures 2 and 3). All these pathways converge on the IKK signaling complex (23,45,46), which is inhibited by N1L (Figure 4). Because IKK-$\alpha$ and IKK-$\beta$ are associated with the large IKK multiprotein complex via their regulatory subunit IKK-$\gamma$ (39), IKK-$\alpha$ and IKK-$\beta$ may be indirectly targeted because both kinases associate with IKK-$\gamma$ which physically associates with N1L (Figure 6A). Other viral proteins have been described that physically associate with IKK-$\gamma$ thereby altering signaling to NF-$\kappa$B (38,47,48).

However, several lines of evidence suggest that N1L does not function by inhibiting the association of IKK-$\alpha$ or IKK-$\beta$ with IKK-$\gamma$. First, indirect evidence against
N1L functioning by association with IKK- is provided by the association of N1L with TBK1 and IKK-(Figure 5B) and vice versa (Figure 5C). TBK1 and IKK- are linked to IKK- by IKK- and TANK, suggesting that a proportion of the IKK- remains associated with IKK- in the presence of N1L. Second, N1L does not interfere with the IKK-IKK- association (Figure 6B), which further suggests that N1L does not target IKK- directly. The limited amount of HA-IKK- associated with N1L (Figure 6A) suggests that N1L may target another member of the IKK-containing multiprotein complex (39). The direct interaction of N1L with TBK1 (Figure 7) suggests that a principal target of N1L is TBK1. Overall, these observations are consistent with the hypothesis that N1L targets the IKK complex by a mechanism that may be distinct from other viruses (38,47,48).

TBK1 is the IKK component that is most strongly implicated as a target of N1L (Figure 8). TBK1 has been shown to be involved in activation of NF- dependent transcription (49-51). Most recently a novel, TBK1-interacting IKK component, NAP-1, has been shown to mediate NF- activation by TBK1 via phosphorylation of the p65 subunit of NF- (52). However, the role of TBK1 in NF- activation is still unclear since some of the effects attributed to TBK1 deficiency cannot reproducibly be linked to NF-, and are instead hypothesized to relate primarily to effects on signaling by interferon regulatory factor 3 (IRF3) (42). TBK1 and IKK- mediate the type I interferon antiviral response (6,42). The data presented here indicate that TBK1 associates with N1L (Figure 7, 5B and 5C), and IKK- associates with N1L less strongly (Figure 7, 5B and 5C). These findings suggested the hypothesis that, in addition to inhibiting NF- activation, N1L might also inhibit IRF3 signaling that is mediated by TBK1 and IKK-.
Figure 8, N1L inhibits IRF3 signaling. Future studies will be needed to further test the hypothesis that the association of N1L with TBK1 interrupts the type I interferon antiviral response that is mediated in part by IRF3.

N1L-mediated inhibition of signaling by TNF superfamily members is a distinct--and perhaps vital--viral immune evasion mechanism. The lymphotoxins (LTs): LT-a, LIGHT, and LT-a1b2 (LT-b), are part of the TNF superfamily (53). The activation of lymphotoxin receptors stimulates antiviral responses (54-56), NF-kB translocation (57), and lymphoid organogenesis. Furthermore, TNF-a itself has potent antiviral effects and can induce programmed cell death in certain virus-infected cells (reviewed in (54,58)). Several viral mechanisms for avoiding immune responses mediated by TNF-a have been described (54,58). Although certain poxviruses encode decoy TNF-a receptors, only certain decoy receptors neutralize LT-a, and no other poxviral lymphotoxin antagonist has been identified to date (59). Thus, N1L-mediated inhibition of the lymphotoxin and TNF-a antiviral pathways may influence the outcome of poxviral infections.

Poxviral inhibitors of signaling inhibit a wider array of cellular anti-viral genes than is possible with a single, virus-encoded soluble decoy receptor. For example, N1L targets signaling by IL-1b, TNF-a, lymphotoxins, and Toll receptors (Figure 1 and 2). Thus, targeting of the IKK complex identifies N1L as a unique vaccinia virus inhibitor of certain antiviral signaling pathways. Simultaneously, N1L is one of several poxvirus proteins that target distinct points in the innate antiviral signaling pathway (17,28), all of which converge at the IKK complex. Furthermore, N1L inhibits signaling by the innate immune pathways that simultaneously suppress vaccinia virus replication (37) and
activate the adaptive immune response (3,4,60). We hypothesize that the much less virulent, yet almost equally immunogenic, phenotype of N1L-deficient vaccinia virus (18) reflects suppression of innate immune signaling by N1L (Figures 1-4, and Figure 8), resulting in increased virulence (18,19) and an inhibited adaptive immune response during wild type vaccinia virus infection in vivo (18). Overall, identification of NF-κB and IRF3 signaling pathways as a target of N1L identifies the role of N1L as a viral protein with novel immunomodulatory properties.
Acknowledgements

We thank Daniel Rowe, Alberto Visintin, Douglas Golenbock, Neal Silverman, Masanori Terajima, and Francis Ennis for advice and assistance, and Harold Hills for sequencing. This work was supported by the American Heart Association (WLM), Science Foundation Ireland (JS, AGB) and The Irish Higher Education Authority (JS, AGB) and the Wellcome Trust (KAF).
REFERENCES

1. Moss, B. (2001) *Poxviridae: The Viruses and their Replication*. In Fields Virology. (Howley, P. M. and Knipe, D. M., Ed.), Lippincott, Williams and Wilkins, Philadelphia, 2849-2883.
2. Bowie, A., Kiss-Toth, E., Symons, J., Smith, G., Dower, S., and LA., O. N. (2000) *Proc Natl Acad Sci U S A* **97**, 10162-10167.
3. Medzhitov, R., and Janeway, C. (1998) *Semin Immunol.* **10**, 351-353.
4. Akira, S., Takeda, K., and Kaisho, T. (2001) *Nat Immunol.* **2**, 675-680.
5. Bin, L., Xu, L., and Shu, H. (2003) *J Biol Chem* **278**, 24526-24532.
6. Fitzgerald, K., McWhirter, S., Faia, K., Rowe, D., Latz, E., Golenbock, D., Coyle, A., Liao, S., and Maniatis, T. (2003) *Nat Immunol.* **4**, 491-496.
7. Fitzgerald, K., Palsson-McDermott, E., Bowie, A., Jefferies, C., Mansell, A., Brady, G., Brint, E., Dunne, A., Gray, P., Harte, M., McMurray, D., Smith, D., Sims, J., Bird, T., and O'Neil, L. (2001) *Nature* **413**, 78.
8. Akira, S., Hoshino, K., and Kaisho, T. (2000) *J Endotoxin Res* **6**, 383-387.
9. Horng, T., Barton, G., and Medzhitov, R. (2001) *Nat Immunol. 2001 Sep;2(9):835-41.***
10. Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., and Seya, T. (2003) *Nat Immunol* **4**, 161-167.
11. Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O., Takeda, K., and Akira, S. (2002) *J Immunol* **169**, 6668-6672.
12. Oshiumi, H., Sasai, M., Shida, K., Fujita, T., Matsumoto, M., and Seya, T. (2003) *J Biol Chem.* **278(4)**, 49751-62.
13. Janssens, S., and Beyaert, R. (2003) *Mol Cell.* **11**, 293-302.
14. Wang, C., Deng, L., Hong, M., Akkaraju, G., Inoue, J., Chen, Z., and Wang, C. (2001) *Nature* **412**, 346–351.
15. Karin, M., and Ben-Neriah, Y. (2000) *Annu Rev Immunol.* **18**, 621-663.
16. Silverman, N., and Maniatis, T. (2001) *Genes Dev.* **15**, 2321-2342.
17. Afonso, C. L., Tulum, E. R., Lu, Z., Zsak, L., Osorio, F. A., Balinsky, C., Kutish, G. F., and Rock, D. L. (2002) *J Virol.* **76**, 783-790.
18. Kotwal, G., Hugin, A., and Moss, B. (1989) *Virology* **171**, 579-587.
19. Bartlett, N., Symons, J., Tscharke, D., and Smith, G. (2002) *J Gen Virol* **83**, 1965-1976.
20. Kurt-Jones, E., Mandell, L., Whitney, C., Padgett, A., Gosselin, K., Newburger, P., and Finberg, R. (2002) *Blood* **100**, 1860-1868.
21. Latz, E., Visintin, A., Lien, E., Fitzgerald, K., Monks, B., Kurt-Jones, E., Golenbock, D., and Espevik, T. (2002) *J Biol Chem.* **277**, 7834-7843.
22. Regnier, C., Song, H., Gao, X., Goeddel, D., Cao, Z., and Rothe, M. (1997) *Cell* **90**, 373-383.
23. Woronicz, J., Gao, X., Cao, Z., Rothe, M., and Goeddel, D. (1997) *Science* **278**, 866-869.
24. Rothe, M., Sarma, V., Dixit, V., and Goeddel, D. (1995) *Science* **269**, 1424-1427.
25. Takeuchi, O., Hoshino, K., and Akira, S. (2000) *J Immunol* **165**, 5392-5396.
26. Takeuchi, O., Kaufmann, A., Kawai, T., Hoshino, K., Morr, M., Mühlradt, P., and Shizuo, A. (2000) *The Journal of Immunology* **164**, 554-557.
27. Harte, M., Haga, I., Maloney, G., Gray, P., Reading, P., Bartlett, N., Smith, G., Bowie, A., and O'Neill, L. (2003) *J Exp Med* **97**, 343-351
28. Bowie, A., Zhan, J., and Marshall, W. (2004) *Journal of Cellular Biochemistry* **91**, 1099-1108
29. Tamada, K., Shimozaki, K., Chapoval, A., Zhai, Y., Su, J., Chen, S., Hsieh, S., Nagata, S., Ni, J., and Chen, L. (2000) *J. Immunol.* **164**, 4105
30. Farrell, P., Rowe, D., Rooney, C., and Kouzarides, T. (1989) *EMBO J.* **8**, 127-132.
31. Dreyfus, D., Nagasawa, M., Pratt, J., Kelleher, C., and Gelfand, E. (1999) *J. Immmol* **163**, 6261-6268
32. Takeuchi, O., and Akira, S. (2002) *Microbes Infec* **4**, 887-895
33. Means, T., Golenbock, D., and Fenton, M. (2000) *Life Sci.* **68**, 241-258
34. Medzhitov, R., Preston-Hurlburt, P., and Janeway, C. J. (1997) *Nature*. **388**, 394-397
35. Ozinsky, A., Underhill, D., Fontenot, J., Hajjar, A., Smith, K., Wilson, C., Schroeder, L., and Aderem, A. (2000) *Proc Natl Acad Sci U S A* **97**, 13766-13771.
36. Dunne, A., and O'Neill, L. (2003), *Science*
37. Hoebe, K., Du, X., Georgel, P., Janssen, E., Tabeta, K., Kim, S., Goode, J., Lin, P., Mann, N., Mudd, S., Crozat, K., Sovath, S., Han, J., and Beutler, B. (2003) *Nature* **424**, 743-748
38. Ye, J., Xie, X., Tarassishin, L., and Horwitz, M. (2000) *J Biol Chem* **275**, 9882-9889.
39. Chariot, A., Leonardi, A., Muller, J., Bonif, M., Brown, K., and Siebenlist, U. (2002) *J Biol Chem* **277**, 37029-37023
40. Tegethoff, S., Behlke, J., and Scheidereit, C. (2002) *Mol. Cell. Biol* **23**, 2029-2041
41. May, M., D'Acquisto, F., Madge, L., Glockner, J., Pober, J., and Ghosh, S. (2000) *Science* **289**, 1550-1554.
42. McWhirter, S., Fitzgerald, K., Rosains, J., Rowe, D., Golenbock, D., and Maniatis, T. (2004) *Proc Natl Acad Sci U S A* **101**, 233-238
43. Takeda, K., Kaisho, T., and Akira, S. (2003) *Ann. Rev. Immunol* **21**, 335-376
44. Fitzgerald, K., Rowe, D., Barnes, B., Caffrey, D., Visintin, A., Latz, E., Monks, B., Pitha, P., and Golenbock, D. (2003) *J Exp Med* in press.
45. Zandi, E., Rothwarf, D., Delhase, M., Hayakawa, M., and Karin, M. (1997) *Cell* **91**, 243-252.
46. Sizemore, N., Lerner, N., Dombrowski, N., Sakurai, H., and Stark, G. (2002) *J Biol Chem.* **277**, 3863-3869
47. Field, N., Low, W., Daniels, M., Howell, S., Daviet, L., Boshoff, C., and Collins, M. (2003) *J Cell Sci.* **116**, 3721-3728
48. Xiao, G., Harhaj, E., and Sun, S. (2000) *J Biol Chem* **275**, 34060-34067.
49. Tojima, Y., Fujimoto, A., Delhase, M., Chen, Y., Hatakeyama, S., Nakayama, K., Kaneko, Y., Nimura, Y., Motoyama, N., Ikeda, K., Karin, M., and Nakanishi, M. (2000) *Nature* **404**, 778-782
50. Pomerantz, J., and Baltimore, D. (1999) *EMBO J.* **18**, 6694-6704.
51. Bonnard, M., Mirtsos, C., Suzuki, S., Graham, K., Huang, J., Ng, M., Itie, A., Wakeham, A., Shahinian, A., Henzel, W., Elia, A., Shillinglaw, W., Mak, T., Cao, Z., and Yeh, W. (2000) *EMBO J.* 19, 4976-4985

52. Fujita, F., Taniguchi, Y., Kato, T., Narita, Y., Furuya, A., Ogawa, T., Sakurai, H., Joh, T., Itoh, M., Delhase, M., Karin, M., and Nakanishi, M. (2003) *Mol Cell Biol* 23, 7780-7793.

53. Granger, S., Butrovich, D., Pantea Houshmand, P., Edwards, W., and Ware, C. (2001) *The Journal of Immunology* 167, 5122–5128.

54. Benedict, C., and Ware, C. (2001) *Virology 2001 Oct 10;289(1):1-5 289*, 1-5

55. Berger, D., Naniche, D., Crowley, M., Koni, P., Flavell, R., and Oldstone, M. (1999) *Virology* 260, 136-147

56. Kumaraguru, U., Davis, I., Deshpande, S., Tevethia, S., and Rouse, B. (2001) *J Immunol 166*, 1066-1074

57. Nakano, H., Oshima, H., Chung, W., Williams-Abbott, L., Ware, C., Yagita, H., and Okumura, K. (1996) *Journal of Biological Chemistry* 271, 14661-14664

58. Benedict, C., Banks, T., and Ware, C. (2003) *Curr Opin Immunol.* 15, 59-65.

59. Reading, P., Khanna, A., and Smith, G. (2002) *Virology 292*, 285-298

60. Schnare, M., Barton, G., Holt, A., Takeda, K., Akira, S., and Medzhitov, R. (2001) *Nat Immunol 2*, 947-950
Figure 1. N1L inhibits signaling by IL-1, TNF and the lymphoksin LIGHT. (A) HEK cells were co-transfected with NF-κB-luciferase and Renilla-luciferase reporters and 0, 50 or 100 ng/well of N1L. At 24 hours following transfection, cells were stimulated with 10 ng/ml of IL-1β, LIGHT, or TNF-α for 4-6 hours. Luciferase activity was measured as described (2) in triplicate wells in three separate experiments. Results were normalized to Renilla luciferase intensity in the same well and are expressed as a ratio to the lowest relative luminescence unit value. These results are representative of at least 4 individual experiments. (B) N1L does not inhibit AP-1 luciferase activity. HEK 293 cells were transfected with one of three reporter constructs: NF-κB luciferase (NF-κB), AP-1 luciferase (AP-1) or NFAT luciferase (NFAT). Constructs were co-transfected with Renilla luciferase and either empty vector or BZLF1 and analyzed as above. These results are representative of three individual experiments.

Figure 2. N1L inhibits signaling by several Toll receptors. (A) N1L inhibits TLR2-dependent signaling in response to lipopeptide agonists. HEK 293 cells transfected with TLR2 were transiently co-transfected with luciferase reporters as above, and N1L or control vector. At 24 hours following transfection cells were stimulated with the indicated ligands. Six hours later luciferase activity was assayed as above. (middle panel) N1L inhibits signaling by transiently cotransfected, constitutively active chimeric CD4-TLR1 and CD4-TLR6. (bottom panel) N1L inhibits signaling by transiently cotransfected CD4-TLR1 and CD4-TLR6. These results are representative of 3 independent experiments.
(B) N1L inhibits stimulation of stable TLR3 transfectants with poly I:C. In five independent experiments, HEK 293 cells stably transfected with TLR3 were transfected with N1L and luciferase reporters, stimulated with the indicated ligand and analyzed 18 hours later as above. (bottom panel) N1L inhibited signaling induced by poly I:C treatment of HEK cells transiently transfected with TLR3. These results are representative of 3 independent experiments. (C) N1L inhibits the response of TLR4 transfectants to LPS. (top panel) HEK 293 cells transfected with TLR4/MD2 were transfected with N1L and luciferase reporters, stimulated with the indicated ligand and analyzed 18 hours later as above. (bottom panel) Signaling by transiently cotransfected CD4-TLR4 was inhibited by N1L. These results are representative of 3 independent experiments.

Figure 3. TIR adapter and TRAF signaling are inhibited by N1L. (A) NFκB signaling the TIR adapters MyD88, TRIF, TRAM and Mal is inhibited by N1L. Several TIR adapters: TRIF, TRAM, MyD88, and Mal/TIRAP were separately co-transfected with NFκB luciferase, Tk-Renilla luciferase reporters and N1L or control empty vector (EV) into HEK 293 cells. At 24 hours following transfection, luciferase activity was assayed in the cell lysates (2). Results with MyD88 and Mal are representative of at least 5 independent experiments, whereas results with TRIF and TRAM are representative of at least 3 independent experiments. (B) Induction of NFκB signaling by TRAF2 and TRAF6 is inhibited by N1L. TRAF2 and TRAF6 cDNAs were separately cotransfected with luciferase reporters as above. NFκB activation was measured as above in the
presence or absence of cotransfected N1L. N1L inhibited NFκB activation induced by TRAF2 and TRAF6 in 3 independent experiments.

Figure 4. N1L inhibits NFκB activation by TBK1, IKK-α and IKK-β. (A) cDNAs encoding IKK-α and IKK-β were separately co-transfected with N1L into HEK 293 cells with luciferase reporters and analyzed as above. N1L inhibited NFκB activation induced by ectopic expression of IKK-α and IKK-β in at least 5 independent experiments. (B) cDNAs encoding IKK-ε and TBK1 were transfected with N1L or vector control and analyzed as above. N1L inhibited NFκB activation induced by ectopic expression of TBK1 and IKK-ε in 3 independent experiments.

Figure 5. N1L associates with components of the IKK signaling complex. (A) IKK-α and IKK β associate with N1L. Top panel: an N1L-HN fusion protein was co-expressed in HEK cells with FLAG-tagged: IKK-α (lane 1), IKK-β (lane 2), and Mal (lane 3). Proteins immunoprecipitated with anti-HN were detected on the blot with anti-FLAG-antibody. The arrow at left denotes the approximate size of IKK-α and IKK-β. Control, FLAG tagged Mal does not co-immunoprecipitate with N1L-6xHN. The bottom panel denotes loading of the N1L-6xHN fusion protein. (B) TBK1 associates with N1L. Top panel: an N1L-HN fusion protein was co-expressed in HEK cells with FLAG-tagged: IKKε (lane 1) and TBK1 (lane 2). Proteins immunoprecipitated with anti-HN were detected on the blot with anti-FLAG-antibody. The arrow at left denotes the approximate size of IKK-ε and TBK1. Control, FLAG tagged TRAF6 does not co-immunoprecipitate with N1L-6xHN. The bottom panel denotes loading of the N1L-6xHN fusion protein. (C) N1L associates
with TBK1. Top panel: FLAG-tagged IKK-\(\gamma\) (lane 1), FLAG-tagged TBK1 (lane 2), and endogenous raf-1 (lane 3) were immunoprecipitated and probed on the blot with anti-HN antibody. The arrow at left denotes the size of HAN1L-6xHN. The bottom panel demonstrates the amount of N1L-6xHN fusion protein in 5% of the lysate from each sample. IP, immunoprecipitation, IB, immunoblot.

Figure 6. TANK and IKK-\(\gamma\) associate with N1L. (A) HEK cells were cotransfected with either HA-TANK or HA-IKK-\(\gamma\) and N1L-6xHN. Lysates were immunoprecipitated as denoted in the figure and proteins detected with anti-HA antibody. (B) IKK-\(\gamma\):IKK-\(\gamma\) associations persist in the presence of N1L. A N1L-HN fusion protein was co-expressed in HEK cells with FLAG-IKK-\(\gamma\) or FLAG-TRAF2. Lysates were immunoprecipitated as denoted in the figure and proteins detected with anti-IKK-\(\gamma\) antibody.

Figure 7. N1L interacts with TBK1 in vitro. Protein-protein interactions were assessed using in vitro transcribed and translated N1L (lane 4) and either IKK-\(\gamma\) (lane 1), TANK (lane 2) or TBK1 (lane 3). Following binding in vitro the proteins were immunoprecipitated, and then analyzed by SDS-PAGE. The arrow at right denotes a 15 kilodalton band in the N1L and TBK1 lanes. A band of approximately 50 kilodaltons is present in the TANK and IKK-\(\gamma\) lanes, consistent with their molecular sizes.

Figure 8. N1L inhibits IRF3 signaling. (A) N1L inhibits activation of the ISRE and the IFN-\(\gamma\) promoter induced by transfection the TIR adapter, TRAM. HEK cells were co-transfected with Renilla-luciferase and either ISRE- or IFN-\(\gamma\)-promoter- luciferase, either
25 ng/well of vector or TRAM, and either 100 ng/well of N1L-encoding plasmid, or empty vector to a total of 200 ng/well. Luciferase activity was measured at 24 hours as described (2). Results are consistent with three experiments. (B) N1L inhibits IRF3 signaling induced by double stranded RNA. HEK cells stably expressing TLR3 were co-transfected with Renilla-luciferase, ISRE-luciferase, and either 100 ng/well of N1L-encoding plasmid, or empty vector to a total of 200 ng/well. Luciferase activity was measured at 24 hours as described (2). Results are consistent with three experiments.
Figure 2

A) HEK-TLR2

![Graph showing Fold NF-κB Activation for Vector and N1L with different treatments.

- Unstimulated
- Purified LPS
- MALP-2
- Unpurified LPS

Fold NF-κB Stimulation for Vector and N1L with CD4TLR1&2 treatment.

- Unstimulated
- CD4TLR1&2

Histograms showing Fold NF-κB Stimulation.
B) HEK-TLR3

Fold NF-κB Activation

- Unstimulated
- poly(I:C)

Vector | N1L
---|---

Fold NF-κB Stimulation

- Unstimulated
- TLR3+poly(I:C)

Vector | N1L
---|---
C) HEK-TLR4

Fold NF-kB Stimulation

- Unstimulated
- LPS
- MALP-2
- unpurified LPS

Fold NF-kB Activation

- Vector
- N1L

Fold NF-kB Stimulation

- Unstimulated
- CD4TLR4

- Vector
- N1L
Figure 3

A)

![Bar graph showing fold NF-kB stimulation for different conditions and receptors. The x-axis represents Vector and N1L, and the y-axis represents fold stimulation. The bars are labeled for Unstimulated, TRIF, TRAM, Mal, and MyD88.]

B)

![Bar graph showing fold NF-kB stimulation for different conditions and receptors. The x-axis represents Vector and N1L, and the y-axis represents fold stimulation. The bars are labeled for Unstimulated, TRAF2, and TRAF6.]}
Figure 4-A)

!![](image)

Fold NF-κB Stimulation

Vector N1L

Unstimulated
IKK-alpha
IKK-beta

Figure 4-B)

!![](image)

Fold NF-κB Stimulation

Vector N1L

TBK1
IKKe
Unstimulated
Figure 5A

IP: anti-6xHN-N1L
IB: anti-FLAG

IKKa IKKb Mal

N1L

105 kDa
75 kDa
50 kDa
35 kDa

20.1 kDa
14.3 kDa
6.5 kDa
Figure 5B
Figure 5C

Anti-HN IB:
- IKKε
- TBK1
- Raf-1

Anti-FLAG IP: N1L

Lysates: N1L
Figure 6A

Anti-HN IP
\(\text{Anti-HA IB:}\)

\[\begin{align*}
\text{TANK} & \quad 75 \text{ kDa} \\
\text{IKK} & \quad 45 \text{ kDa} \\
\text{30 kDa} & \\
\text{20 kDa} & \\
\text{Anti-HN IB:} & \\
\text{HAN1LHN} & \quad 30 \text{ kDa} \\
\text{20 kDa} & \\
\text{14.3 kDa} & 
\end{align*}\]
**Figure 6B**

| IP with anti- | FLAG | FLAG | FLAG |
|---------------|------|------|------|
| FLAG-IKKβ     | +    | -    | +    |
| FLAG-TRAF2    | -    | +    | -    |
| 6xHN-N1L      | +    | -    | -    |

IP; anti-IKKγ blot

Lysates; anti-IKKγ blot
Figure 7

N1L+
IKK-γ TANK TBK1 N1L

105 kDa
75 kDa —
50 kDa —
35 kDa —
15 kDa —
10 kDa —
Figure 8

A)

Fold Luciferase Stimulation

0 5 10

TRAM Vector N1L Vector

ISREluc IFNBluc

B)

Fold activation of ISRE luciferase

0 2.5 5 7.5

vector Vector N1L

Poly(i:C) Media
Poxvirus protein N1L targets the I-κB kinase complex, inhibits signaling to NF-κB by the tumor necrosis factor superfamily of receptors, and inhibits NF-κB and IRF3 signaling by toll-like receptors

Gary DiPerna, Julianne Stack, Andrew G. Bowie, Annemarie Boyd, Girish Kotwal, Zhouning Zhang, Sheila Arvikar, Eicke Latz, Katherine A. Fitzgerald and William L Marshall

J. Biol. Chem. published online June 23, 2004

Access the most updated version of this article at doi: 10.1074/jbc.M400567200

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts